Etelcalcetide

Etelcalcetide
Clinical data
Trade names	Parsabiv
Other names	Velcalcetide, telcalcetide, AMG-416, KAI-4169, ONO-5163
AHFS/Drugs.com	Monograph
MedlinePlus	a617011
License data	US DailyMed: Etelcalcetide;
Routes of; administration	Intravenous injection
ATC code	H05BX04 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	3–5 days in dialysis patients
Excretion	60% in dialysate, 7% in urine and faeces
Identifiers
	IUPAC name (6R,9R,12R,15R,18R,21R,24S,29R)-24-Acetamido-1,29-diamino-12,15,18-tris(3-carbamimidamidopropyl)-6-carbamoyl-1-imino-9,21-dimethyl-8,11,14,17,20,23-hexaoxo-26,27-dithia-2,7,10,13,16,19,22-heptaazatria contan-30-oic acid;
CAS Number	1262780-97-1; as salt: 1334237-71-6;
PubChem CID	71511839;
DrugBank	DB12865; as salt: DBSALT002195;
ChemSpider	32697932; as salt: 32698192;
UNII	60ME133FJB; as salt: 72PT5993DU;
KEGG	D10676; as salt: D10677;
ChEMBL	as salt: ChEMBL3545183;
CompTox Dashboard (EPA)	DTXSID70155132 ;
Chemical and physical data
Formula	C38H73N21O10S2
Molar mass	1048.26 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C;
	InChI InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1; Key:ANIAZGVDEUQPRI-ZJQCGQFWSA-N; ; as salt: InChI=1S/C38H73N21O10S2.ClH/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69;/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52);1H/t18-,19-,21+,22-,23-,24-,25-,26-;/m1./s1; Key:KHQMSZGKHGQUHG-WZDHWKSBSA-N;

Etelcalcetide, sold under the brand name Parsabiv, is a calcimimetic medication for the treatment of secondary hyperparathyroidism in people undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.